US Edition
Swallowing the Needle: How Oral Wegovy Could Reshape the GLP-1 Boom
Summary by Daily-remedy.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Swallowing the Needle: How Oral Wegovy Could Reshape the GLP-1 Boom
A Pill That Dares to Outgrow Its Injection There are moments in drug development when a technical tweak—an extended-release coating here, a new isomer there—merely polishes yesterday’s idea. And then there are moments when a formulation re-writes an industry’s emotional contract with patients. On May 2, 2025, the U.S. Food & Drug Administration accepted Novo Nordisk’s New Drug Application for oral Wegovy, a once-daily 25 mg tablet of semaglutide…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
